Canada Pension Plan Investment Board Has $140,000 Stock Position in Bruker Co. (NASDAQ:BRKR)

Canada Pension Plan Investment Board decreased its position in Bruker Co. (NASDAQ:BRKR) by 95.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,200 shares of the medical research company’s stock after selling 49,600 shares during the period. Canada Pension Plan Investment Board’s holdings in Bruker were worth $140,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in BRKR. Assetmark Inc. raised its holdings in Bruker by 24.7% in the 4th quarter. Assetmark Inc. now owns 1,005 shares of the medical research company’s stock valued at $74,000 after acquiring an additional 199 shares in the last quarter. Treasurer of the State of North Carolina raised its holdings in Bruker by 1.0% in the 4th quarter. Treasurer of the State of North Carolina now owns 48,608 shares of the medical research company’s stock valued at $3,572,000 after acquiring an additional 468 shares in the last quarter. TFO Wealth Partners LLC raised its holdings in shares of Bruker by 30,866.7% in the 4th quarter. TFO Wealth Partners LLC now owns 929 shares of the medical research company’s stock worth $68,000 after buying an additional 926 shares in the last quarter. KBC Group NV raised its holdings in shares of Bruker by 6.6% in the 4th quarter. KBC Group NV now owns 38,051 shares of the medical research company’s stock worth $2,796,000 after buying an additional 2,356 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB acquired a new position in shares of Bruker in the 4th quarter worth approximately $1,176,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Up 0.3 %

NASDAQ:BRKR opened at $70.67 on Friday. Bruker Co. has a 12-month low of $53.79 and a 12-month high of $94.86. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $10.27 billion, a P/E ratio of 25.70, a P/E/G ratio of 2.43 and a beta of 1.18. The stock’s fifty day simple moving average is $65.08 and its 200-day simple moving average is $71.96.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.52. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The business had revenue of $800.70 million for the quarter, compared to analyst estimates of $799.44 million. During the same period last year, the company earned $0.50 EPS. The firm’s revenue was up 17.4% on a year-over-year basis. Equities research analysts expect that Bruker Co. will post 2.61 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were given a $0.05 dividend. The ex-dividend date of this dividend was Friday, August 30th. This represents a $0.20 annualized dividend and a dividend yield of 0.28%. Bruker’s dividend payout ratio is currently 7.27%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BRKR shares. TD Cowen dropped their target price on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a report on Wednesday, August 7th. Jefferies Financial Group started coverage on Bruker in a report on Monday, June 3rd. They issued a “buy” rating and a $85.00 target price for the company. Citigroup dropped their target price on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. The Goldman Sachs Group dropped their price target on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. Finally, Wells Fargo & Company began coverage on Bruker in a report on Tuesday, August 27th. They set an “overweight” rating and a $78.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $81.40.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.